Understanding Why Cardinal Health Stock Is Moving Up Today.

Cardinal Health stock is trading -8.76% below its average target price of $114.08 after marking a 3.1% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $95.0 to $129.0 per share.

The stock has an average amount of shares sold short at 4.4%, and a short ratio of 3.74. The company's insiders own 0.58% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 91.4% of Cardinal Health's shares being owned by this investor type.

Institutions Invested in Cardinal Health

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 13% 30,620,279 $3,187,264,728
2024-03-31 Blackrock Inc. 11% 27,335,699 $2,845,372,808
2024-03-31 State Street Corporation 6% 14,112,384 $1,468,957,998
2024-03-31 FMR, LLC 2% 5,796,164 $603,322,689
2024-03-31 Geode Capital Management, LLC 2% 5,574,144 $580,212,628
2024-03-31 Morgan Stanley 2% 4,366,078 $454,465,043
2024-03-31 Arrowstreet Capital, Limited Partnership 2% 4,140,014 $430,934,042
2024-03-31 Pacer Advisors, Inc. 2% 3,728,901 $388,141,291
2024-03-31 Acadian Asset Management. LLC 2% 3,723,159 $387,543,606
2024-03-31 Ameriprise Financial, Inc. 1% 3,623,872 $377,208,823

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Cardinal Health.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.